Inventor · disambiguated record
Jason Harris
Also filed as: HARRIS JASON · HARRIS JASON R · HARRIS JASON RANDALL
23 granted patents·30 pending applications·174 citations·filing 2010–2024
94Inventor score
Files withGLOBAL BLOOD THERAPEUTICS INC18ESCALIER BIOSCIENCES B V9OPPILAN PHARMA LTD7VENTYX BIOSCIENCES INC5ZOMAGEN BIOSCIENCES LTD5
Top patents by PatentIndex Score
53 records- 0197US9957250B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2015·Granted May 1, 2018·19 cites·6 claims
- 0297US9802900B2Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2014·Granted Oct 31, 2017·39 cites·20 claims
- 0396US10695330B2Methods of treatmentGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Granted Jun 30, 2020·12 cites·17 claims
- 0496US9604999B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2013·Granted Mar 28, 2017·45 cites·3 claims
- 0593US9981939B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2014·Granted May 29, 2018·17 cites·7 claims
- 0692US10100040B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2014·Granted Oct 16, 2018·18 cites·21 claims
- 0790US10266551B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2014·Granted Apr 23, 2019·16 cites·21 claims
- 0880US11753411B2Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligandsVENTYX BIOSCIENCES INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 0980US2023277527A1Ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2023·Application pending·0 cites
- 1080US2024216361A1Ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2023·Application pending·0 cites
- 1179US2023322704A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1277US2023339944A1Heterocyclic compounds for the treatment of diseaseOPPILAN PHARMA LTD·Filed 2023·Application pending·0 cites
- 1376US2024101571A1Nlrp3 modulatorsZOMAGEN BIOSCIENCES LTD·Filed 2023·Application pending·0 cites
- 1475US11530191B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·0 cites·4 claims
- 1574US2022175765A1Ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2022·Application pending·0 cites
- 1674US2022402940A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1773US8637499B2Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufactureAAY NAING·Filed 2010·Granted Jan 28, 2014·5 cites·23 claims
- 1873US2023183258A1Nlrp3 modulatorsZOMAGEN BIOSCIENCES LTD·Filed 2023·Application pending·0 cites
- 1971US2022227767A1Heterocyclic compounds for the treatment of diseaseOPPILAN PHARMA LTD·Filed 2022·Application pending·0 cites
- 2070US2022119407A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2170US2023406858A1Tyk2 pseudokinase ligandsVENTYX BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2269US2023348478A1Tyk2 pseudokinase ligandsVENTYX BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2369US2021069182A1Ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2020·Application pending·0 cites
- 2467US11236109B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2019·Granted Feb 1, 2022·0 cites·8 claims
- 2567US10829470B2Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·0 cites·11 claims
- 2667US2023312589A1Jak inhibitorsVIMALAN BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2767US2024315994A1Small molecule modulators of ferroptosisARPEGGIO BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2866US11603375B2NLRP3 modulatorsZOMAGEN BIOSCIENCES LTD·Filed 2021·Granted Mar 14, 2023·0 cites·20 claims
- 2965US8648066B2Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufactureANAND NEEL KUMAR·Filed 2010·Granted Feb 11, 2014·2 cites·34 claims
- 3063US2020325135A1Heterocyclic compounds for the treatment of diseaseOPPILAN PHARMA LTD·Filed 2020·Application pending·0 cites
- 3163US2016024127A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3262US2022106329A1Bicyclic ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2021·Application pending·0 cites
- 3362US2022106323A1Spirocyclic ror-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2021·Application pending·0 cites
- 3461US10683291B2Heterocyclic compounds for the treatment of diseaseOPPILAN PHARMA LTD·Filed 2016·Granted Jun 16, 2020·0 cites·14 claims
- 3560US10905687B2Substituted piperazines as ROR-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2017·Granted Feb 2, 2021·0 cites·21 claims
- 3660US2014274961A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 3759US11242350B2Spirocyclic ROR-gamma modulatorsESCALIER BIOSCIENCES B V·Filed 2019·Granted Feb 8, 2022·0 cites·20 claims
- 3859US11230555B2Bicyclic RORγ modulatorsESCALIER BIOSCIENCES B V·Filed 2019·Granted Jan 25, 2022·0 cites·19 claims
- 3958US2019010176A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4058US2024010649A1Crystalline forms of an s1p receptor modulatorOPPILAN PHARMA LTD·Filed 2023·Application pending·0 cites
- 4157US11780842B2TYK2 pseudokinase ligandsVENTYX BIOSCIENCES INC·Filed 2020·Granted Oct 10, 2023·0 cites·19 claims
- 4256US11459333B2Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitorsVIMALAN BIOSCIENCES INC·Filed 2020·Granted Oct 4, 2022·0 cites·20 claims
- 4356US2015057251A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 4455US2024261414A1Fatty acid amide hydrolase (faah) cleavable prodrugs of brain targeting actives and combination with peripherally restricted faah inhibitorsAUTOBAHN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4554US2024254075A1Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitorsAUTOBAHN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4651US12466800B2N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)ZOMAGEN BIOSCIENCES LTD·Filed 2020·Granted Nov 11, 2025·0 cites·19 claims
- 4751US12351564B2NLRP3 modulatorsZOMAGEN BIOSCIENCES LTD·Filed 2020·Granted Jul 8, 2025·0 cites·20 claims
- 4848US2023024521A1Jak inhibitorsVIMALAN BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4947US2017355713A1Compounds and uses thereof for the modulation of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 5045US11136329B2JAK inhibitorsVIMALAN BIOSCIENCES INC·Filed 2020·Granted Oct 5, 2021·0 cites·19 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jason Harris files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →